Moreover, our data could be consistent with the synergistic activity observed in MM and mantle cell lymphoma preclinical models, between BET bromodomain inhibitor (MYC transcriptional inhibitor) and lenalidomide [42,43]. Here, MYC is linked to mantle cell lymphoma.